Viridian Therapeutics Inc (VRDN)

$12.7

-0.18

(-1.4%)

Market is closed - opens 7 PM, 23 May 2024

Insights on Viridian Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 7 quarters, 1.19M → 72.0K (in $), with an average decrease of 20.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -66.86M → -48.54M (in $), with an average increase of 37.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.0% return, outperforming this stock by 113.0%

Performance

  • $12.67
    $13.24
    $12.70
    downward going graph

    0.24%

    Downside

    Day's Volatility :4.31%

    Upside

    4.08%

    downward going graph
  • $10.93
    $28.35
    $12.70
    downward going graph

    13.94%

    Downside

    52 Weeks Volatility :61.45%

    Upside

    55.2%

    downward going graph

Returns

PeriodViridian Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-32.34%
-0.9%
0.0%
6 Months
-22.13%
12.3%
0.0%
1 Year
-48.95%
12.7%
0.0%
3 Years
19.47%
17.8%
-20.1%

Highlights

Market Capitalization
822.0M
Book Value
$6.0
Earnings Per Share (EPS)
-4.49
Wall Street Target Price
36.5
Profit Margin
0.0%
Operating Margin TTM
-77634.72%
Return On Assets TTM
-29.24%
Return On Equity TTM
-46.75%
Revenue TTM
288.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-26.5%
Gross Profit TTM
-99.1M
EBITDA
-237.3M
Diluted Eps TTM
-4.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.7
EPS Estimate Next Year
-3.93
EPS Estimate Current Quarter
-1.1
EPS Estimate Next Quarter
-1.11

Analyst Recommendation

Buy
    95%Buy
    4%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Viridian Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
21
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 187.4%

Current $12.70
Target $36.50

Company Financials

FY18Y/Y Change
Revenue
8.4M
↑ 109.49%
Net Income
-32.7M
↑ 23.35%
Net Profit Margin
-389.97%
↑ 272.33%
FY19Y/Y Change
Revenue
4.5M
↓ 46.8%
Net Income
-42.4M
↑ 29.71%
Net Profit Margin
-950.91%
↓ 560.94%
FY20Y/Y Change
Revenue
1.1M
↓ 76.46%
Net Income
-111.0M
↑ 161.63%
Net Profit Margin
-10.6K%
↓ 9618.99%
FY21Y/Y Change
Revenue
3.0M
↑ 182.19%
Net Income
-79.4M
↓ 28.44%
Net Profit Margin
-2.7K%
↑ 7889.64%
FY22Y/Y Change
Revenue
1.8M
↓ 40.2%
Net Income
-125.4M
↑ 57.96%
Net Profit Margin
-7.1K%
↓ 4398.97%
FY23Y/Y Change
Revenue
314.0K
↓ 82.28%
Net Income
-237.7M
↑ 89.51%
Net Profit Margin
-75.7K%
↓ 68632.23%
Q4 FY22Q/Q Change
Revenue
105.0K
↓ 91.21%
Net Income
-42.5M
↑ 51.66%
Net Profit Margin
-40.5K%
↓ 38134.81%
Q1 FY23Q/Q Change
Revenue
98.0K
↓ 6.67%
Net Income
-68.0M
↑ 60.09%
Net Profit Margin
-69.4K%
↓ 28954.69%
Q2 FY23Q/Q Change
Revenue
72.0K
↓ 26.53%
Net Income
-55.1M
↓ 19.08%
Net Profit Margin
-76.5K%
↓ 7041.7%
Q3 FY23Q/Q Change
Revenue
72.0K
↑ 0.0%
Net Income
-47.7M
↓ 13.44%
Net Profit Margin
-66.2K%
↑ 10281.95%
Q4 FY23Q/Q Change
Revenue
72.0K
↑ 0.0%
Net Income
-66.9M
↑ 40.29%
Net Profit Margin
-92.9K%
↓ 26666.67%
Q1 FY24Q/Q Change
Revenue
72.0K
↑ 0.0%
Net Income
-48.5M
↓ 27.4%
Net Profit Margin
-67.4K%
↑ 25441.67%
FY18Y/Y Change
Total Assets
66.1M
↑ 26.04%
Total Liabilities
14.8M
↑ 5.96%
FY19Y/Y Change
Total Assets
30.3M
↓ 54.25%
Total Liabilities
14.5M
↓ 1.99%
FY20Y/Y Change
Total Assets
131.3M
↑ 333.73%
Total Liabilities
11.2M
↓ 22.68%
FY21Y/Y Change
Total Assets
203.7M
↑ 55.2%
Total Liabilities
16.0M
↑ 42.57%
FY22Y/Y Change
Total Assets
435.1M
↑ 113.58%
Total Liabilities
40.0M
↑ 150.28%
FY23Y/Y Change
Total Assets
490.4M
↑ 12.72%
Total Liabilities
48.4M
↑ 20.92%
Q4 FY22Q/Q Change
Total Assets
435.1M
↓ 1.25%
Total Liabilities
40.0M
↑ 26.78%
Q1 FY23Q/Q Change
Total Assets
386.6M
↓ 11.14%
Total Liabilities
36.1M
↓ 9.83%
Q2 FY23Q/Q Change
Total Assets
351.5M
↓ 9.1%
Total Liabilities
35.6M
↓ 1.34%
Q3 FY23Q/Q Change
Total Assets
328.8M
↓ 6.46%
Total Liabilities
45.2M
↑ 26.88%
Q4 FY23Q/Q Change
Total Assets
490.4M
↑ 49.18%
Total Liabilities
48.4M
↑ 7.13%
Q1 FY24Q/Q Change
Total Assets
630.4M
↑ 28.54%
Total Liabilities
47.9M
↓ 1.14%
FY18Y/Y Change
Operating Cash Flow
-26.8M
↓ 4.7%
Investing Cash Flow
-29.9M
↓ 2992.36%
Financing Cash Flow
41.9M
↓ 20.11%
FY19Y/Y Change
Operating Cash Flow
-36.1M
↑ 34.32%
Investing Cash Flow
28.2M
↓ 194.38%
Financing Cash Flow
70.0K
↓ 99.83%
FY20Y/Y Change
Operating Cash Flow
-29.8M
↓ 17.41%
Investing Cash Flow
-50.5M
↓ 278.85%
Financing Cash Flow
101.3M
↑ 144630.0%
FY21Y/Y Change
Operating Cash Flow
-54.6M
↑ 83.29%
Investing Cash Flow
-74.3M
↑ 47.17%
Financing Cash Flow
125.3M
↑ 23.65%
FY22Y/Y Change
Operating Cash Flow
-93.8M
↑ 71.92%
Investing Cash Flow
-115.1M
↑ 54.96%
Financing Cash Flow
322.2M
↑ 157.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-34.0M
↑ 64.71%
Investing Cash Flow
-180.6M
↓ 523.44%
Financing Cash Flow
26.0M
↓ 91.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-62.0M
↑ 82.05%
Investing Cash Flow
-13.3M
↓ 92.64%
Financing Cash Flow
8.2M
↓ 68.46%
Q2 FY23Q/Q Change
Operating Cash Flow
-45.2M
↓ 27.04%
Investing Cash Flow
40.7M
↓ 406.23%
Financing Cash Flow
3.1M
↓ 62.6%

Technicals Summary

Sell

Neutral

Buy

Viridian Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viridian Therapeutics Inc
Viridian Therapeutics Inc
-10.88%
-22.13%
-48.95%
19.47%
19.47%
Moderna, Inc.
Moderna, Inc.
51.39%
108.01%
18.57%
-0.51%
663.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.43%
23.24%
31.43%
96.58%
212.06%
Novo Nordisk A/s
Novo Nordisk A/s
4.19%
27.1%
63.97%
228.1%
454.07%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.53%
26.76%
34.19%
111.88%
158.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viridian Therapeutics Inc
Viridian Therapeutics Inc
NA
NA
NA
-3.7
-0.47
-0.29
NA
6.0
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.33
29.33
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.45
46.45
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.65
28.65
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viridian Therapeutics Inc
Viridian Therapeutics Inc
Buy
$822.0M
19.47%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.1B
663.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$109.5B
212.06%
29.33
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.1B
454.07%
46.45
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$114.1B
158.67%
28.65
39.46%

Institutional Holdings

  • FMR Inc

    11.95%
  • Paradigm Biocapital Advisors LP

    7.51%
  • Perceptive Advisors LLC

    5.73%
  • Deep Track Capital, LP

    5.69%
  • BlackRock Inc

    5.37%
  • Vanguard Group Inc

    5.07%

Company Information

miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research

Organization
Viridian Therapeutics Inc
Employees
94
CEO
Mr. Stephen F. Mahoney J.D., MBA
Industry
Healthcare

FAQs